Osteosarcoma - Pipeline Insight, 2025

This “Osteosarcoma - Pipeline Insight, 2025” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Osteosarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Osteosarcoma: Understanding

Osteosarcoma: Overview

Osteosarcoma, also known as osteogenic sarcoma, is a rare type of bone cancer that originates in the bones, specifically affecting the long bones like those around the knee and shoulder. This cancer primarily develops in children and teenagers who are still growing. The exact cause of osteosarcoma is not fully understood, although in some instances, there is a familial predisposition with at least one gene associated with an increased risk. The hallmark symptom of osteosarcoma is pain, which can start intermittently but usually progresses to become constant. Patients may also experience swelling, a noticeable mass near the tumor site, or in cases where the cancer affects the leg bones, it can lead to limping. Notably, some osteosarcomas can be asymptomatic, adding to the challenge of early detection.

Diagnosing osteosarcoma involves a comprehensive approach that includes a thorough medical history review, physical examination, and a series of imaging tests such as X-rays, CT scans, MRIs, bone scans, and PET scans. A definitive diagnosis is confirmed through a biopsy of the suspected tumor. Treatment for osteosarcoma typically involves a combination of chemotherapy, surgery, and in some cases, radiation therapy. Chemotherapy is often administered before surgery to shrink the tumor, making it easier to remove. Post-surgery, chemotherapy may be used to eliminate any remaining cancer cells. Radiation therapy, although less common in osteosarcoma treatment, can be an alternative to surgery in certain cases.

The prognosis for osteosarcoma varies depending on factors like the stage of the cancer, the location of the tumor, and the patient's overall health. Early detection and a multidisciplinary treatment approach involving oncologists, surgeons, and other specialists are crucial for improving outcomes. Patients with osteosarcoma may require limb-sparing surgery, amputation in severe cases, or rotationplasty for tumors around the knee joint. These surgical interventions aim to remove the cancer while preserving limb function and quality of life. Additionally, ongoing research is focused on developing more effective chemotherapy regimens and targeted therapies to enhance treatment outcomes for osteosarcoma patients. Treatment for osteosarcoma typically involves a multimodal approach combining chemotherapy, surgery, and occasionally radiation therapy. Chemotherapy is often administered before surgery to shrink the tumor, making it more operable, and may continue post-surgery to target any remaining cancer cells. Surgical intervention aims to remove the tumor while preserving limb function whenever possible, utilizing techniques like limb-sparing surgery, amputation in advanced cases, or rotationplasty around the knee joint. Radiation therapy, though less common, can be an alternative to surgery in select situations.

'Osteosarcoma- Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Osteosarcoma pipeline landscape is provided which includes the disease overview and Osteosarcoma treatment guidelines. The assessment part of the report embraces, in depth Osteosarcoma commercial assessment and clinical Assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Osteosarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Osteosarcoma R&D. The therapies under development are focused on novel approaches to treat/improve Osteosarcoma.

Osteosarcoma Emerging Drugs Chapters

This segment of the Osteosarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, Phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Osteosarcoma Emerging Drugs

HS-20093: Hansoh BioMedical R&D Company

HS-20093 is a novel B7-H3-targeted antibody-drug conjugate that consists of a fully humanized anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor (TOPOi) payload. This innovative drug is being developed for the treatment of lung cancer, sarcoma, head and neck cancers, and other solid tumors through multiple phase I and II clinical trials in China. The mechanism of action (MOA) of HS-20093 involves the specific targeting of B7-H3, a transmembrane receptor highly prevalent on malignant cells, with the monoclonal antibody component. This targeting allows for the delivery of the topoisomerase inhibitor payload directly to the cancer cells, where it can exert its cytotoxic effects, potentially leading to tumor cell death and inhibition of tumor growth. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Osteosarcoma.

ZN c3: Zentalis Pharmaceuticals

ZN-c3 is a combination with gemcitabine used in adult and pediatric subjects with relapsed or refractory osteosarcoma. ZN-c3 is a phase I/II drug, developed by Zentalis Pharmaceuticals. ZN-c3 drug is an investigational drug and gemcitabine is an approved drug. ZN-c3 have received a fast track designation for uterine cancer but is under phase I/II for osteosarcoma.

NPX267: Nextpoint Therapeutics

NPX267 is a first-in-class monoclonal antibody targeting KIR3DL3, the inhibitory receptor for the HHLA2 pathway (B7-H7), and is designed to prevent immune escape in solid tumors. By blocking the binding of KIR3DL3 on exhausted T and NK cells to HHLA2 expressed on tumor cells, NPX267 may be able to reactivate tumor antigen-primed immune cells in HHLA2-expressing solid tumors. Preventing KIR3DL3-mediated immune suppression may enhance anti-tumor immune responses for patients with HHLA2-positive cancers - a tumor antigen expressed independently of PD-L1. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Osteosarcoma.

Osteosarcoma: Therapeutic Assessment

This segment of the report provides insights about the different Osteosarcoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Osteosarcoma

• There are approx. 25+ key companies which are developing the therapies for Osteosarcoma. The companies which have their Osteosarcoma drug candidates in the most advanced stage, i.e. Phase III include, Hansoh BioMedical R&D Company.

Phases

The report covers around 30+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Osteosarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Osteosarcoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Osteosarcoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Osteosarcoma drugs.

Osteosarcoma Report Insights

• Osteosarcoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Osteosarcoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Osteosarcoma drugs?
• How many Osteosarcoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Osteosarcoma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Osteosarcoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Osteosarcoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Zentalis Pharmaceuticals
• MedPacto
• Salarius Pharmaceuticals
• NextPoint Therapeutics
• Base Therapeutics
• EMD Serono
• Hansoh BioMedical R&D Company
• Cellectar Biosciences
• OS Therapies
• AlaMab Therapeutics

Key Products

• ZN-c3
• Vactosertib
• Seclidemstat
• NPX267
• NK510
• M6620
• HS-20093
• CLR 131
• ADXS 31164
• ALMB-0166

This product will be delivered within 1-3 business days.